

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John D. PLUENNEKE

Serial No.: 10/712,122

Group Art Unit No.: 1614

Filed: November 13, 2003

Examiner: Unknown

For: METHODS OF TREATMENT USING AN INHIBITOR OF EPIDERMAL

GROWTH FACTOR RECEPTOR

Docket No.: 3369-A

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Respectfully submitted,

Rosemary Sweeney

Attorney/Agent for Applicant

Registration No.: 52,264 Phone: (206) 265-7817

Date: May 28, 2004

Please send all future correspondence to:

Immunex Corporation Law Department 1201 Amgen Court West Seattle, WA 98119-3105 (206) 265-7000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Signatus

| Sheet | 1 | Of | 2 |
|-------|---|----|---|
| | | | |

| Modified Form PTO-1449 | Atty. Docket No. | Serial No. |
|---|-------------------|------------|
| SIPE | 3369-A | 10/712.122 |
| LIST OF REFERENCES CITED BY APPLICANT | Applicant | |
| | John D. PLUENNEKE | |
| HIM () 1 200, (Use several sheets if necessary) | Filing Date | Group |
| JUN 0 1 2004 (Case several sheets in necessary) | November 13, 2003 | 1614 |

| 115 | DΔ. | TFNT | DOCI | JMENTS | |
|------|-----|------|------|-----------|---|
| 0.0. | | | | JINIEITIO | , |

| EXAMINE | 100 | U.S. PATENT DOCUMENTS | | | | | | |
|-------------|------------|-----------------------|-------------|----------------------|-------|---|-------------------------------|--|
| EXAMINE NO. | BER | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE | |
| | A1 | 2002/0001587 | 01/03/2002 | Erickson et al. | | | | |
| | A2 | 2002/0012663 | 01/31/2002 | Waksal | | | | |
| | А3 | 2002/0034736 | 03/21/2002 | Falb et al. | | | | |
| | A4 | 2002/0058033 | 05/16/2002 | Raisch et al. | | | | |
| | A 5 | 2002/0065398 | 05/30/2002 | del Rio et al. | | | | |
| | A6 | 2002/0102685 | 08/01/2002 | Sibilia et al. | | | | |
| | A7 | 2002/0107284 | 08/08/2002 | Uckun et al. | | | | |
| | A8 | 5,183,805 | 02/02/1993 | Lee et al. | | | | |
| | A9 | 5,459,061 | 10/17/1995 | Sato et al. | | | | |
| | A10 | 5,558,864 | 09/24/1996 | Bendig et al. | | | | |
| | A11 | 5,770,195 | 06/23/1998 | Hudziak | | | | |
| | A12 | 5,844,093 | 12/01/1998 | Kettleborough et al. | | | | |
| | A13 | 5,874,528 | 02/23/1999 | Lupu et al. | | | | |
| | A14 | 5,891,996 | 04/06/1999 | del Rio et al. | | | | |
| | A15 | 5,894,018 | 04/13/1999 | Davila et al. | | | | |
| | A16 | 5,914,269 | 06/22/1999 | Bennett et al. | | | | |
| | A17 | 5,981,725 | 11/09/1999 | Vogelstein et al. | | | | |
| | A18 | 6,057,156 | 05/02/2000 | Akhtar et al. | | | | |
| | A19 | 6,127,344 | 10/03/2000 | Amici et al. | | | | |
| | A20 | 6,129,915 | 10/10/2000 | Wels et al. | | | | |
| | A21 | 6,187,585 | 02/13/2001 | Bennett et al. | | | | |
| | A22 | 6,217,866 | 04/17/2001 | Schlessinger et al. | | | | |
| | A23 | 6,224,868 | 05/01/2001 | Wong et al. | | | | |
| | A24 | 6,235,883 | 05/22/2001 | Jakobovits et al. | | | | |
| | | | | | | | | |
| | L | | | | | _ــــــــــــــــــــــــــــــــــــــ | | |

| EXAMINER: | Date Considered: |
|-----------|------------------|
| | |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Sheet | 2 | Of | 3 |
|-------|---|----------|---|
| 0001 | | <u> </u> | |

| | | | | | | Sheet 2 | 2 Of | 3_ |
|------------------------|-----------|---|-------------------|--|----------------|---------------|---------------|-------------|
| Modified Fo | rm PTO-14 | 149 | | Atty. Docket No. 3369-A | Seria | | 0/712.12 | 2 |
| LI | ST OF R | REFERENCES CITED B | APPLICANT | Applicant | | | 311 12.12 | |
| | | (Continued) | | John D. PLUENN Filing Date | NEKE Grou | | | |
| | | (Continued) | | November 13, 20 | 1 | | 614 | |
| | | | FORFIGN PAT | FNT DOCUMENTS | | | | |
| EXAMINER'S INITIALS | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSI YES | ATION NO |
| | B1 | 0 566 226 B1 | 11/08/1995 | EP | | | | |
| | B2 | 0 667 165 B1 | 03/27/2002 | EP | | | | |
| | В3 | 1 170 011 A1 | 01/09/2002 | EP | | | | |
| | B4 | WO 95/20045 | 07/27/1995 | PCT | | | | |
| | B5 | WO 95/24190 | 09/14/1995 | PCT | | | | |
| | B6 | WO 96/30347 | 10/03/1996 | PCT | | | | |
| | B7 | WO 96/40648 | 12/19/1996 | PCT | | | | |
| | B8 | WO 97/41226 | 11/06/1997 | PCT | | | | |
| | B9 | | | | | | | |
| EXAMINER'S INITIALS | | OTHER DOCUMENTS | 6 (Including Pu | blisher, Author, Title, Date, | , Pertinen | t Pages | , Etc.) | |
| | C1 | | | growth factor level is predictive on the contractive of the contraction of the contractio | | | in wom | en |
| | C2 | Ciardiello F and Tortor factor receptor," Clin C | | oach in the treatment of cancer: 3-2970, 2001. | targeting th | ne epider | mal gro | wth |
| | C3 | Crombet-Ramos T et al., "Pharmacological and clinical evaluation of the humanized anti EGF-R monoclonal antibody, h-R3, in patients with advanced epitherlial carcinomas," 2001 ASCO Annual Meeting, May 12-15, 2001, San Francisco, CA, Abstract No. 1012. | | | | | | |
| | C4 | Di Lieto A et al., "EGF/EGF-R system and benign breast disease during and following the treatment of gynaecological pathologies with an analogue of LH-RH," <i>Clin Exp Obst Gyn</i> , XXIII(4):220-228, 1996. | | | | | | |
| | C5 | Dorrance AM et al., "Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats," <i>Am J Physiol Regulatory Integrative Comp Physiol</i> , 281:R944-R950, 2001. | | | | | | |
| | C6 | Heldin C-H, "Signal transduction: multiple pathways, multiple options for therapy," <i>Stem Cells</i> 19:295-303, 2001. | | | | | | |
| | C7 | Hess JC et al., "Growth factor profiles in breast cyst fluid identify women with increased breast cancer risk," <i>Am J Surg</i> , 167:523-530, 1994. | | | | | | |
| | C8 | l e | after permanent r | growth factor-α acting at the ep middle cerebral artery occlusion | • | | • | |
| | C9 | ' | • | in-binding epidermal growth fact ceptor," <i>Gastroenterology</i> , 116:7 | • | | in rat g | astric |

| EXAMINER: | Date Considered: |
|---|---|
| Liverine 1. | Date Considered. |
| | |
| | |
| | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation | if not in conformance and not considered. Include copy of this form with next |
| communication to applicant. | • |
| Continuation to applicant | |

| Sheet | 3 | Of | 3 |
|-------|---|----|---|

| | | Silect | 3 | Oi | 3 |
|---------------------------------------|-------------------|------------|------|--------|---|
| Modified Form PTO-1449 | Atty. Docket No. | Serial No. | | | |
| | 3369-A | | 10/7 | 12.122 | ! |
| LIST OF REFERENCES CITED BY APPLICANT | Applicant | | | | |
| | John D. PLUENNEKE | | | | |
| (Continued) | Filing Date | Group | | | |
| | November 13, 2003 | | 1614 | 4 | |

. . . · ·

| EXAMINER'S INITIALS | C | OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.) |
|------------------------|-----|--|
| | C10 | Nicholson RI et al., "EGFR and cancer prognosis," Eur J Cancer, 37:S9-S15, 2001. |
| | C11 | Nishi E et al., "Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes," <i>Circ Res</i> , 80:638-644, 1997. |
| | C12 | Noble F et al., "International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors," <i>Pharmacol Rev</i> , 51(4):745-781, 1999. |
| | C13 | Pavelic K et al., "Evidence for a role of EGF receptor in the progression of human lung carcinoma," Anticancer Res, 13:1133-1138, 1993. |
| | C14 | Rozengurt E and Walsh JH, "Gastrin, CCK, signaling, and cancer," <i>Annu Rev Physiol</i> 63:49-76, 2001. |
| | C15 | Sambhi MP et al., "Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of pressor angiotensin II," <i>Biochem Med Metab Biol</i> , 48:8-18, 1992. |
| | C16 | Schaer J-C and Reubi JC, "High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents," <i>J Clin Endocrinol Metab</i> , 84:233-239, 1999. |
| | C17 | Shaw JP et al., "Cytotoxic properties of DAB ₄₈₆ EGF and DAB ₃₈₉ EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins," <i>J Biol Chem</i> , 266(31):21118-21124, 1991. |
| | C18 | Smith AM et al., "Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer," <i>Clin Cancer Res</i> , 6:4719-4724, 2000. |
| | C19 | Smith AM and Watson SA, "Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence," <i>Gut</i> , 47:820-824, 2000. |
| | C20 | Swaminathan N et al., "Elevated epidermal growth factor receptor levels in hypertensive lyon rat kidney and aorta," <i>Clin Exp Pharmacol Physiol</i> , 23:793-796, 1996. |
| | C21 | Ullrich A et al., "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells," <i>Nature</i> , 309:418-425, 1984. |
| | C22 | Watson SA et al., "Transforming growth factor-a-mediated growth pathways in human gastro-intestinal cell lines in relation to the gastrin autocrine pathway," <i>Int J Cancer</i> , 87:20-28, 2000. |
| | C23 | Zwick E et al., "Receptor tyrosine kinase signalling as a target for cancer intervention strategies," Endocrine-Related Cancer, 8:161-173, 2001. |
| | C24 | |
| | C25 | · |
| | C26 | |

| EXAMINER: | Date Considered: |
|--|--|
| | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if communication to applicant. | not in conformance and not considered. Include copy of this form with next |